Combinations of modalities for the treatment of diabetes

Abstract

A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule and a Type 1 diabetes autoantigen. Pharmaceutical compositions are also provided herewith.

1 .- 19 . (canceled) 
     
     
         20 . A pharmaceutical composition comprising:
 about 0.5 to about 10 mg of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) fusion protein,   about 250 mg to about 2000 mg of a preproinsulin, and   an oil-based carrier that is IFA or Montanide ISA pharmaceutically acceptable carrier.   
     
     
         21 . The pharmaceutical composition of  claim 20 , wherein said CTLA4 fusion protein is abatacept.